Zacks reiterated their neutral rating on shares of ISIS Pharmaceuticals (NASDAQ: ISIS) in a research note issued to investors on Monday. The firm currently has a $16.00 target price on the stock.

Zacks’ analyst wrote, “Isis Pharmaceuticals Inc.’s net loss of $0.21 per share in the fourth quarter of 2012 was a penny wider than the year-ago loss but narrower than the Zacks Consensus Estimate of loss of $0.23 per share. Revenues decreased 38.7% to $19.9 million, beating the Zacks Consensus Estimate of $16 million. We are positive on Isis’ agreements with Glaxo, AstraZeneca and Biogen, which not only validated its antisense technology but also provided Isis with funds in the form of upfront, milestone and other payments. We are also encouraged by the approval of Kynamro in the US in Jan 2013. However we remain worried that concerns regarding the safety profile of Kynamro. This has the potential to limit its commercial potential. Apart from that, competitor Aegerion Pharmaceuticals received US approval for Juxtapid in Dec 2012 for homozygous familial hypercholesterolemia (HoFH). We maintain a Neutral recommendation on the stock.”

A number of other analysts have also recently weighed in on ISIS. Analysts at Liberum Capital initiated coverage on shares of ISIS Pharmaceuticals in a research note to investors on Friday, February 15th. They set a hold rating and a $69.00 price target on the stock. Separately, analysts at Piper Jaffray raised their price target on shares of ISIS Pharmaceuticals to $11.00 in a research note to investors on Wednesday, January 30th. Finally, analysts at Needham & Company raised their price target on shares of ISIS Pharmaceuticals from $14.00 to $18.00 in a research note to investors on Wednesday, January 30th. They now have a buy rating on the stock.

Four analysts have rated the stock with a buy rating, four have given a hold rating, and one has issued a sell rating to the stock. ISIS Pharmaceuticals currently has an average rating of overweight and an average price target of $13.71.

Shares of ISIS Pharmaceuticals traded up 1.40% during mid-day trading on Monday, hitting $17.39. ISIS Pharmaceuticals has a 52 week low of $7.02 and a 52 week high of $17.44. The stock’s 50-day moving average is currently $14.42. The company’s market cap is $1.761 billion.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.